Save information for later
Sign Up

Learn About Common Variable Immune Deficiency

What is the definition of Common Variable Immune Deficiency?

Common variable immune deficiency (CVID) is a disorder that impairs the immune system. People with CVID are highly susceptible to infection from foreign invaders such as bacteria, or more rarely, viruses and often develop recurrent infections, particularly in the lungs, sinuses, and ears. Pneumonia is common in people with CVID. Over time, recurrent infections can lead to chronic lung disease. Affected individuals may also experience infection or inflammation of the gastrointestinal tract, which can cause diarrhea and weight loss. Abnormal accumulation of immune cells causes enlarged lymph nodes (lymphadenopathy) or an enlarged spleen (splenomegaly) in some people with CVID. Immune cells can accumulate in other organs, forming small lumps called granulomas.

What are the causes of Common Variable Immune Deficiency?

The cause in CVID is unknown in approximately 90 percent of cases. It is likely that this condition is caused by both environmental and genetic factors. While the specific environmental factors are unclear, the genetic influences in CVID are believed to be mutations in genes that are involved in the development and function of immune system cells called B cells. B cells are specialized white blood cells that help protect the body against infection. When B cells mature, they produce special proteins called antibodies (also known as immunoglobulins). These proteins attach to foreign particles, marking them for destruction. Mutations in the genes associated with CVID result in dysfunctional B cells that cannot make sufficient amounts of antibodies.

How prevalent is Common Variable Immune Deficiency?

CVID is estimated to affect 1 in 25,000 to 1 in 50,000 people worldwide, although the prevalence can vary across different populations.

Is Common Variable Immune Deficiency an inherited disorder?

Most cases of CVID are sporadic and occur in people with no apparent history of the disorder in their family. These cases probably result from a complex interaction of environmental and genetic factors.

Who are the top Common Variable Immune Deficiency Local Doctors?
John R. Hurst
Elite in Common Variable Immune Deficiency
Elite in Common Variable Immune Deficiency
Pond Street, 
London, ENG, GB 

John Hurst practices in London, United Kingdom. Mr. Hurst is rated as an Elite expert by MediFind in the treatment of Common Variable Immune Deficiency. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Common Variable Immune Deficiency, Bronchiectasis, and Acute Interstitial Pneumonia.

Elite in Common Variable Immune Deficiency
Allergy and Immunology
Elite in Common Variable Immune Deficiency
Allergy and Immunology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
Languages Spoken:
English

Charlotte Cunningham-Rundles is an Allergy and Immunologist in New York, New York. Dr. Cunningham-Rundles is rated as an Elite provider by MediFind in the treatment of Common Variable Immune Deficiency. Her top areas of expertise are Common Variable Immune Deficiency, Primary Immunodeficiency (PID), X-Linked Agammaglobulinemia, and Immunodeficiency with Hyper IgM Type 1.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Common Variable Immune Deficiency
Elite in Common Variable Immune Deficiency
Rome, IT 

Isabella Quinti practices in Rome, Italy. Ms. Quinti is rated as an Elite expert by MediFind in the treatment of Common Variable Immune Deficiency. Her top areas of expertise are Common Variable Immune Deficiency, Primary Immunodeficiency (PID), X-Linked Agammaglobulinemia, Selective Deficiency of IgA, and Splenectomy.

What are the latest Common Variable Immune Deficiency Clinical Trials?
A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency (CVID)

Summary: In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefit...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomised Platform Trial Evaluating the Role of Interventions to Prevent Infection in Patients With Acquired Hypogammaglobulinemia Secondary to Haematological Malignancies - RATIONAL-PT (Core)

Summary: This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers. It is a comparison between Immunoglobulin and antibiotics use.

Who are the sources who wrote this article ?

Published Date: May 01, 2016
Published By: National Institutes of Health